ReviewFrontiers in cell and developmental biology2024
Moving from lipids to leukocytes: inflammation and immune cells in atherosclerosis.
Review in Frontiers in cell and developmental biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- CD80 as an Important Immune Mediator and Therapeutic Target in Atherosclerosis.International journal of molecular sciences · 2026Review
- Article
- The negative association between C-reactive protein-albumin-lymphocyte index and cardiovascular disease.The Journal of international medical research · 2026Article
- Comparative value of novel inflammatory indices in predicting incident carotid atherosclerosis: SIRI outperforms other markers in a general population.Frontiers in cardiovascular medicine · 2026Article
- Prognostic significance of the CALLY index for mortality among patients with cardiovascular-kidney-metabolic syndrome stages 0-3.Diabetology & metabolic syndrome · 2025Article
- Anti-inflammatory interventions in coronary artery disease: antipodal responses requiring targeted therapeutic strategies.Basic research in cardiology · 2025Review
- Estimating inflammatory risk in atherosclerotic cardiovascular disease: plaque over plasma?European heart journal. Cardiovascular Imaging · 2025Review
- Association Between Systemic Immune-Inflammatory Indices and Severity of Coronary Artery Lesions in Patients With Coronary Artery Disease in Different Glucose Metabolic States.Journal of inflammation research · 2025Article
- Dyslipidemia in severe fever with thrombocytopenia syndrome patients: A retrospective cohort study.PLoS neglected tropical diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is the most important cause of morbidity and mortality worldwide. While it is traditionally attributed to lipid accumulation in the vascular endothelium, recent research has shown that plaque inflammation is an important additional driver of atherogenesis. Though clinical outcome trials utilizing anti-inflammatory agents have proven promising in terms of reducing ASCVD risk, it is imperative to identify novel actionable targets that are more specific to atherosclerosis to mitigate adverse effects associated with systemic immune suppression. To that end, this review explores the contributions of various immune cells from the innate and adaptive immune system in promoting and mitigating atherosclerosis by integrating findings from experimental studies, high-throughput multi-omics technologies, and epidemiological research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.